HKSE · 1801.HK
Innovent Biologics, Inc.
HK$81.95+HK$0.35 (+0.43%)
Innovent Biologics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 27.28% below the high.
Loading market information…
HKSE · 2696.HK · HKD
Stock price, earnings
Quote as of Oct 30, 2026, 03:28 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
Shanghai Henlius Biotech, Inc.’s quoted price sits in the lower half of its reported 52-week range, 42.96% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Shanghai Henlius Biotech, Inc.’s next earnings report is currently expected on Mar 19, 2027, with estimated earnings per share of HK$0.99. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Shanghai Henlius Biotech, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Shanghai Henlius Biotech, Inc. functions as a biopharmaceutical enterprise, dedicated to the research and advancement of biologic medicines, with a primary focus on cancer, autoimmune conditions, and ophthalmic disorders. Its commercial portfolio encompasses several approved biologic treatments. Specifically, it markets HANLIKANG, a rituximab injection utilized for non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis; HANQUYOU, a trastuzumab injection indicated for breast and metastatic gastric cancer; HANDAYUAN, an adalimumab injection for rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, and uveitis; HANBEITAI, a bevacizumab injection with indications in metastatic colorectal cancer (mCRC) and non-squamous non-small cell lung cancer (nsNSCLC); and HANSIZHUANG, a serplulimab injection for microsatellite instability-high solid tumors. In addition to its marketed products, Shanghai Henlius is actively progressing its robust development pipeline, which includes Serplulimab, undergoing further development for applications such as squamous non-small cell lung cancer (sqNSCLC), extensive small-cell lung cancer, metastatic esophageal squamous-cell carcinomas, neo-/adjuvant treatment of gastric cancer, hepatocellular carcinoma, mCRC, nsNSCLC, squamous cell carcinoma of the head and neck (SCCHN), and a range of other solid tumor types. Among its other investigational compounds are HLX04-O, a bevacizumab injection aimed at wet age-related macular degeneration; HLX22 for breast and metastatic gastric cancer; a group of therapies—HLX07, HLX23, HLX35, HLX208, HLX55, HLX301, and HLX20—collectively aimed at solid tumors; HLX11 for breast cancer; HLX05, a cetuximab injection for mCRC and SCCHN; HLX12, addressing gastric cancer, metastatic non-small cell lung cancer, and mCRC; and HLX14, designed to treat osteoporosis. Further expanding its pipeline, HLX26 is being developed for solid tumors and lymphoma; HLX13 is under investigation for melanoma, renal cell carcinoma, and mCRC; HLX15 for multiple myeloma; and HLX71, with potential for treating COVID-19. The firm conducts its operations across Mainland China, Europe, the broader Asia-Pacific region, and various other international territories. Founded in 2010, its headquarters are situated in Shanghai, China. Shanghai Henlius Biotech, Inc. operates as a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:43 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2024 |
|---|
| Aug 26, 2024 |
| HK$0.76 |
| HK$2.95B |
| Q4 2023 | Mar 21, 2024 | HK$0.39 | HK$1.49B-77.84% vs estimate |
|---|
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
HK$81.95+HK$0.35 (+0.43%)
Innovent Biologics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 27.28% below the high.
HK$83.40-HK$0.10 (-0.12%)
Akeso, Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.51% below the high.
HK$13.73-HK$0.02 (-0.15%)
3SBio Inc.’s quoted price sits in the lower half of its reported 52-week range, 61.21% below the high.
HK$18.02-HK$0.58 (-3.12%)
Mabwell-b’s quoted price sits in the lower half of its reported 52-week range, 38.25% below the high.
HK$9.88+HK$0.03 (+0.3%)
HBM Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 42.15% below the high.
HK$37.00+HK$0.02 (+0.05%)
Nanjing Leads Biolabs Co Ltd’s quoted price sits in the lower half of its reported 52-week range, 62.05% below the high.
HK$1.58HK$0.00 (0.0%)
Edding Genor Group Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 59.62% below the high.
HK$0.43-HK$0.01 (-1.15%)
Mabpharm Limited’s quoted price sits in the lower half of its reported 52-week range, 46.91% below the high.
